An investment-report writing agent that combines numerical market data with written industry research. It organizes the result into a company, financial, industry, momentum, risk, and overall-assessment review.
A research agent for the pharmaceutical and biotechnology industries. It uses numerical data from another research agent and outside sources such as clinical-trial databases, bio-research sources, and PubMed to interpret industry context, competitors, and clinical progress.
An analysis agent for South Korean pharmaceutical and biotechnology stocks, using clinical-trial data and delegated research and report-writing agents.
Claude Code instructions for hjsh200219/trading-by-clinical-trial, a project described as: Korean pharma clinical trial intelligence — MCP server + Claude Code plugin. 100-point scoring, 6 analysis skills, 32 companies.
A Korean pharmaceutical and biotechnology stock-analysis skill that combines clinical-trial data from ClinicalTrials.gov with technical indicators from Naver Finance.
An analysis of global clinical-trial competition for a specific medical condition or trial, identified by its NCT ID. It maps other ongoing trials in the same treatment area and their sponsors.
A summary of Korean pharmaceutical and biotechnology companies’ drug-development pipelines, including rankings by active clinical trials, phase breakdowns, and the nearest upcoming catalyst.
A clinical-trial-based scoring analysis for Korean pharmaceutical and biotechnology stocks. It calculates scores across six components and shows decision labels.
A technical-analysis skill for South Korean pharmaceutical and biotechnology stocks using public Yahoo Finance data. Technical analysis studies price and trading-volume patterns with measures such as RSI and Bollinger Bands.
A time-ordered list of upcoming clinical-trial completion events for Korean pharmaceutical and biotechnology companies within a chosen number of months. A catalyst is an event that may affect how a company or drug is viewed.